15 Best Micro and Small Cap Stocks to Buy According to Jim Simons’ Renaissance Technologies

9. Pacira Biosciences Inc (NASDAQ:PCRX)

Renaissance Technologies Equity Stake: $41.26 Million

Number of Hedge Fund Holders: 30

Stock Upside Potential: 22.36%

Market Cap: $910.9 Million

Pacira Biosciences Inc (NASDAQ:PCRX) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to pop more than 20% from its current level.

Pacira Biosciences Inc (NASDAQ:PCRX) reported its Q1 2026 results on April 30. It said revenue jumped 5% YoY to $177.4 million and surpassed the projected $172.46 million. The company recorded growth across its commercial portfolio, including a 7% increase in Exparel sales volume. Exparel is the company’s flagship product, and it contributed more than 80% of the company’s total revenue.

Pacira Biosciences delivered a GAAP net income of $2.9 million, compared with $4.8 million in the prior year as it faced higher expenses in areas like research programs. The company wrapped up the quarter with $202.2 million in cash. It spent $50 million on share buybacks during the quarter.

Looking ahead, Pacira Biosciences expects full-year 2026 total revenue in the range of $745 million to $770 million. Exparel sales are projected in the band of $600 million to $620 million.

As it works to grow sales with its existing commercial portfolio, Pacira Biosciences is also advancing its various pipeline projects. The company expects topline data from the Phase 2 ASCEND study of its PCRX-201 program by the end of 2026. PCRX-201 is a gene therapy for treating knee osteoarthritis, a condition that affects some 15 million Americans.

Pacira Biosciences Inc (NASDAQ:PCRX) develops non-opioid pain management solutions. The company has several commercial products along with several pipeline projects. The company’s solutions are designed to address unmet medical needs in the targeted fields.